The Latest Cardiac and Vascular News
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2024. Total revenues in the second quarter of 2024 grew 20 percent year-over-year to $714.9 million, compared to $596.5 million in the second […]
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2024. Third Quarter Fiscal 2024 Financial Summary Total Revenue of $30.3 million, compared to $52.5 million in […]
Los Angeles, July 31, 2024 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM) (“BioSig” or “Company”), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization for electrophysiology (EP) procedures, today announced the intent to acquire the assets of Neuro-Kinesis Corporation (NKC), a privately held Los Angeles-based medical technology company developing smart EP tools.
IRVINE, Calif., July 30, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its second quarter ended June 30, 2024.
NEW HOPE, Pa., July 30, 2024 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of John Mack to its Board of Directors, effective as of July 29, 2024. Mr. Mack brings over 30 years of medical device, healthcare technology, and finance experience to the Company. Mr. Mack most recently served as President of Cardiac Surgery at Medtronic plc., where he successfully led the division to market leadership. During his tenure at Medtronic, he also served as Vice President & General Manager, Extracorporeal Therapies and Vice President, Business Development, Strategy & Portfolio Management where he led the business development operations for the coronary and structural heart business, a $3.2B global enterprise with over 12,000 employees.
MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2024.
ATLANTA, July 25, 2024 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2024 financial results will be released on Thursday, August 8, 2024 after the market closes. On that day, the…
Los Angeles, CA 90025, July 25, 2024 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM) or (“BioSig” or “Company”), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, is pleased to announce that it has successfully negotiated with multiple vendors an initial reduction in accounts payable of approximately $1.5 million during the second quarter of 2024 since new management has taken leadership.
July 25, 2024 08:00 AM Eastern Daylight Time CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing. The financing was led by Ally Bridge […]
July 24, 2024 08:00 AM Eastern Daylight Time KIRKLAND, Wash.–(BUSINESS WIRE)–Kestra Medical Technologies, Inc., a privately held wearable medical device and digital healthcare company, today announced an oversubscribed $196 million funding round to support the expansion of their commercial organization and advance its mission of protecting at-risk patients with its […]
